QNCX
Quince Therapeutics, Inc.Company Information
- Company Name
- Quince Therapeutics, Inc.
- CIK
- CIK0001662774
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- QNCX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- QNCX
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-08-30
- Last sale
- 2025-12-26
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 50,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 330,065
- Shares outstanding
- 6,132,845
- Ownership
- 5.38%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -7.99%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 116 | 18 | 6 | 6 | 17 | 8 | 6 | 3 | 8 | 22 | 21 | 22 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Current | - | - | 12 | 20 | 18 | 24 | 35 | - | - | - | - | - | ||||||
| Available For Sale Securities Debt Securities Current | - | - | - | - | - | - | 35 | 45 | 52 | 46 | 54 | 62 | ||||||
| Short Term Investments | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 7 | 7 | 5 | 3 | 3 | 2 | 3 | 4 | 4 | 3 | 2 | 1 | ||||||
| Assets Current | 123 | 26 | 23 | 29 | 37 | 34 | 44 | 52 | 63 | 70 | 77 | 85 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | 0 | 0 | 68 | 68 | 68 | 62 | 60 | 65 | 62 | 62 | 64 | 0 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Goodwill | - | - | - | - | - | - | 0 | 0 | 0 | 17 | 18 | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 2 | 12 | 11 | 10 | 10 | 10 | 9 | 8 | 9 | - | ||||||
| Assets | 124 | 27 | 94 | 110 | 117 | 107 | 114 | 127 | 135 | 159 | 168 | 85 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 5 | 5 | 2 | 3 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 0 | ||||||
| Accrued Liabilities Current | 4 | 3 | 11 | 5 | 6 | 5 | 4 | 4 | 3 | 3 | 3 | 2 | ||||||
| Long Term Debt Current | 0 | 0 | 18 | 18 | - | - | 0 | - | - | - | - | - | ||||||
| Business Combination Contingent Consideration Liability Current | 0 | 0 | 12 | - | - | - | 0 | 0 | 5 | 5 | 4 | - | ||||||
| Liabilities Current | 9 | 9 | 43 | 26 | 7 | 8 | 7 | 5 | 10 | 10 | 10 | 2 | ||||||
| Long Term Debt | - | - | 0 | 0 | 17 | 15 | 14 | 15 | 14 | 14 | 13 | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 0 | 0 | 52 | 61 | 59 | 59 | 57 | 55 | 57 | 56 | 54 | - | ||||||
| Deferred Income Tax Liabilities Net | - | - | 0 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 0 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Liabilities | 16 | 11 | 129 | 109 | 105 | 89 | 84 | 82 | 88 | 85 | 83 | 2 | ||||||
Temporary Equity | ||||||||||||||||||
| Redeemable Noncontrolling Interest Equity Preferred Carrying Amount | 144 | - | - | - | - | - | - | - | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 460 | 436 | 419 | 416 | 413 | 408 | 407 | 405 | 404 | 403 | 402 | 393 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 4 | 5 | 6 | 6 | 6 | 2 | -0 | 3 | 1 | 2 | 3 | 1 | ||||||
| Retained Earnings Accumulated Deficit | -500 | -425 | -460 | -421 | -408 | -392 | -376 | -364 | -359 | -331 | -320 | -311 | ||||||
| Stockholders Equity | -35 | 16 | -36 | 1 | 12 | 19 | 30 | 45 | 47 | 74 | 85 | 83 | ||||||
| Liabilities And Stockholders Equity | 124 | 27 | 94 | 110 | 117 | 107 | 114 | 127 | 135 | 159 | 168 | 85 | ||||||
| Series A Preferred Stock | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - | ||||||
| Temporary Equity Par Or Stated Value Per Share | 0.00 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Temporary Equity Shares Authorized | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Temporary Equity Shares Issued | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Temporary Equity Shares Outstanding | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 100 | 250 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 1 | 14 | 56 | 54 | 0 | 0 | 44 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 1 | 14 | 56 | 54 | 0 | 0 | 44 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialQuince Therapeutics, Inc. (QNCX) — SEC Financial Statements & Analysis
Quince Therapeutics, Inc. (QNCX) is a biological products, (no diagnostic substances) company, incorporated in CA. Quince Therapeutics, Inc. trades on Nasdaq as: QNCX. Quince Therapeutics, Inc. (QNCX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Quince Therapeutics, Inc. carries a market cap of $111.56M, a P/E ratio of -1.21x, a P/B ratio of -3.16x, an enterprise value of $-4.42M, and an EV/EBITDA multiple of 0.03x. On profitability, it posts a Return on Equity (ROE) of 784.09%, a Return on Assets (ROA) of -76.68%, and a Return on Invested Capital (ROIC) of -146.24%. Per share, it reports EPS of $-15.08, diluted EPS of $-15.08, free cash flow per share of $-8.97, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 88.61% year-over-year and EPS growth of -92.82% year-over-year. On the balance sheet, it maintains a current ratio of 14.52x, a quick ratio of 13.64x, working capital of $114.91M, a debt-to-equity ratio of -0.44x, a debt ratio of 0.13, free cash flow of $-55.00M (TTM), and net debt of $-115.98M. Figures sourced from SEC EDGAR.
- Market Cap
- $111.56M
- P/E TTM
- -1.21x
- EPS TTM
- $-15.08
- P/B TTM
- -3.16x
- ROE TTM
- 784.09%
- ROA TTM
- -76.68%
- Debt To Equity
- -0.44x
- Free Cash Flow TTM
- $-55.00M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Quince Therapeutics, Inc. in?
Quince Therapeutics, Inc. (QNCX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does QNCX trade on?
Quince Therapeutics, Inc. (QNCX) trades on the Nasdaq.
Where is Quince Therapeutics, Inc. incorporated?
Quince Therapeutics, Inc. is incorporated in CA.
When was Quince Therapeutics, Inc. (QNCX)'s most recent SEC filing?
Quince Therapeutics, Inc. (QNCX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is QNCX's market cap?
Quince Therapeutics, Inc. (QNCX) has a market capitalization of $111.56M as of 2026-06-30.
What is QNCX's EPS (earnings per share)?
Quince Therapeutics, Inc. (QNCX)'s trailing twelve month EPS is $-15.08 as of 2026-06-30.
What is QNCX's ROE (return on equity)?
Quince Therapeutics, Inc. (QNCX)'s trailing twelve month Return on Equity (ROE) is 784.09% as of 2026-06-30.
What is QNCX's ROA (return on assets)?
Quince Therapeutics, Inc. (QNCX)'s trailing twelve month Return on Assets (ROA) is -76.68% as of 2026-06-30.
What is QNCX's ROIC (return on invested capital)?
Quince Therapeutics, Inc. (QNCX)'s trailing twelve month Return on Invested Capital (ROIC) is -146.24% as of 2025-09-30.
What is QNCX's EV/EBITDA?
Quince Therapeutics, Inc. (QNCX)'s trailing twelve month EV/EBITDA is 0.03x as of 2026-06-30.